Twilio Shares Jump; 2 Surging Healthcare Stocks

CSBR and CLRB are both huge gainers today

Jul 17, 2018 at 2:28 PM
facebook X logo linkedin


The Dow is trading higher today, as traders digest earnings and comments from Fed Chair Jerome Powell. Three names making notable moves are cloud concern Twilio Inc (NYSE:TWLO), healthcare specialist Champions Oncology Inc (NASDAQ:CSBR), and drugmaker Cellectar Biosciences Inc (NASDAQ:CLRB). Below, we'll take a closer look at how shares of TWLO, CSBR, and CLRB are trading on the charts. 

Bull Note Lifts TWLO Shares to Fresh High

TWLO stock received a price-target hike to $75 from $57 -- in uncharted territory -- at Dougherty, and has gained over 4.6% to trade at $63.96 today. In addition, TWLO earlier hit an annual high of $64.26. It's been a spectacular year for Twilio; thanks to two post-earnings bull gaps it's jumped more than 170% in 2018 -- though it's still staring up at its September 2016 record peak of $70.96. This outperformance has earned the security the confidence of analysts, with 13 of the 14 in coverage handing out "buy" or better ratings.

Meanwhile, put activity has reached extreme levels at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) -- which is likely due, at least partially, to shareholders protecting paper profits. Specifically, Twillio's 10-day put/call volume ratio across these exchanges stands at 1.24 -- an annual high.

Analyst Expects CSBR Shares to Double

A new "buy" rating and $12 price target from Craig-Hallum has CSBR stock spiking today, last seen up 22.6% at $7.14. The new price target represents expected upside of 106% to Champions Oncology stock's close of $5.82 yesterday.

However, the shares earlier stalled out near the $7.50 level, just below their June two-year highs. Longer term, the equity has mostly been trending higher since touching a multi-year low in August 2016, including a 175% jump in the past 12 months. Craig-Hallum becomes just the third brokerage firm to initiate coverage on the oncology technology provider, with the other two also recommending it as a "buy."

$13 Level Blocks Another CLRB Breakout

CLRB shares are up 13.5% at $8.50, after the company announced upbeat results for a mid-stage trial, with one patient seeing a 94% reduction in tumors after receiving Cellectar Biosciences' CLR 131. Still, the stock earlier hit a speed bump again near the $13 area, which has been a stiff ceiling all year. Nevertheless, the equity is still up roughly 42% since hitting an all-time low below the $6 mark earlier this month.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI